GW873140 In Combination With Combivir In HIV Infected Subjects
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.
Human Immunodeficiency Virus I Infection
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||See Detailed Description|
- Proportion of subjects with viral loads <400 copies/mL remaining on randomized treatment through Week 12
- - Comparison of safety and tolerability of different dosage regimens of GW873140 plus Combivir to standard of care regimen. - Assessment of drug resistance over time. - Co-receptor tropism following virological failure.
|Study Start Date:||January 2005|
A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with Combivir (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults
Please refer to this study by its ClinicalTrials.gov identifier: NCT00104429
Show 51 Study Locations
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|